Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Ji'nan, Shandong, PR China.
Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, 4001, South Africa.
Eur J Med Chem. 2019 Dec 1;183:111696. doi: 10.1016/j.ejmech.2019.111696. Epub 2019 Sep 14.
Cell division cycle 25 (Cdc25) protein phosphatases play key roles in the transition between the cell cycle phases and their association with various cancers has been widely proven, which makes them ideal targets for anti-cancer treatment. Though several Cdc25 inhibitors have been developed, most of them displayed low activity and poor subtype selectivity. Therefore, it is extremely important to discover novel small molecule inhibitors with potent activities and significant selectivity for Cdc25 subtypes, not only served as drugs to treat cancer but also to probe its mechanism in transitions. In this study, miniaturized parallel click chemistry synthesis via CuAAC reaction followed by in situ biological screening were used to discover selective Cdc25 inhibitors. The bioassay results showed that compound M2N12 proved to be the most potent Cdc25 inhibitor, which also act as a highly selective Cdc25C inhibitor and was about 9-fold potent than that of NSC 663284. Moreover, M2N12 showed remarkable anti-growth activity against the KB-VIN cell line, equivalent to that of PXL and NSC 663284. An all-atom molecular dynamics (MD) simulation approach was further employed to probe the significant selectivity of M2N12 for Cdc25C relative to its structural homologs Cdc25A and Cdc25B. Overall, above results make M2N12 a promising lead compound for further investigation and structural modification.
细胞分裂周期蛋白 25(Cdc25)蛋白磷酸酶在细胞周期各阶段的转换中发挥着关键作用,其与各种癌症的关联已得到广泛证实,这使其成为抗癌治疗的理想靶点。尽管已经开发出几种 Cdc25 抑制剂,但它们大多数活性低且对亚型的选择性差。因此,发现具有强活性和对 Cdc25 亚型显著选择性的新型小分子抑制剂非常重要,不仅可作为治疗癌症的药物,还可用于探究其在转换中的作用机制。在本研究中,采用 CuAAC 反应的微型化平行点击化学合成,随后进行原位生物筛选,用于发现选择性 Cdc25 抑制剂。生物测定结果表明,化合物 M2N12 被证明是最有效的 Cdc25 抑制剂,也是一种高选择性的 Cdc25C 抑制剂,其活性比 NSC 663284 高约 9 倍。此外,M2N12 对 KB-VIN 细胞系表现出显著的抗增殖活性,与 PXL 和 NSC 663284 相当。进一步采用全原子分子动力学(MD)模拟方法探究了 M2N12 对 Cdc25C 的显著选择性,与结构同源物 Cdc25A 和 Cdc25B 相比。总体而言,上述结果使 M2N12 成为进一步研究和结构修饰的有前途的先导化合物。